glp-1 drug liraglutide may protect against dementia Drugs Target the Roots of GLP-1 drug Liraglutide may protect

Epithalon Studies on Tumor Growth Pathways Rodent experiments have investigated Epithalon in the context of cancer research, with particular attention to its potential modulation of circadian-related genes

doi:10.3389/fmicb.2018.03344

Important Safety Information Regarding Compounded Glutathione Products Please be aware that compounded drugs are not FDA-approved and do not undergo the clinical studies required to evaluate safety and efficacy for commercially available products

We specifically discuss the structure and pharmacological properties of TT-OAD2, LY3502970, and PF-06882961, and envision an era where more patients could benefit from oral GLP-1 receptor agonist therapy

Whether this dose should be maintained for long-term treatment is currently being investigated in the BOND study, which evaluates the effects of 12 months of benfotiamine treatment (300 mg twice daily) on morphometric, neurophysiological and clinical parameters in individuals with T2D and mild-to-moderate symptomatic DPN [73]